News Lilly falls on slower start for Foundayo versus Wegovy Sky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.
News Medicare obesity drug pilot extended after insurer pushback Medicare will cover the cost of a pilot of weight-loss drug coverage, after health insurers refuse to take part.
News Jazz and Lilly cancer drugs cleared for use by NHS Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.
News Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.
News Lilly says Foundayo safety confirmed in ACHIEVE-4 trial Eli Lilly's ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.
News Most patients "won't see benefit" with Alzheimer's drugs A review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.